VastCon's lead technology is a simple, low cost, sensitive and specific blood test for early detection of colorectal cancer. Our test can be performed in any clinical or diagnostic laboratory. The technology, based on a patent pending discovery of biomarkers that are exclusively overexpressed in the peripheral blood of CRC patients, has the potential to replace the current fecal occult blood test (FOBT), a $6 billion market per year in North America and Europe alone.
Co-founder